Adherence to CONSORT-PRO Extension Guidelines for Patient-Reported Outcomes in Randomized Controlled Trials Focused on Peripheral Nerve Blocks: A Meta-epidemiological Study
Authors:
Open Access
- 6 August 2025
- journal article
- research article
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (5) , 1531-1546
Abstract
Introduction Patient-reported outcomes (PROs), such as peri- and postoperative pain scores, capture patient perspectives in regional anesthesia trials. However, whether these outcomes are reported according to established guidelines remains unclear. The CONSORT statement and its PRO extension (CONSORT-PRO) aim to enhance transparency in reporting PROs, yet no study has investigated adherence in peripheral nerve block (PNB) trials. Our meta-epidemiological investigation evaluated how well PNB randomized controlled trials (RCTs) adhere with CONSORT-PRO and explored whether trial characteristics affect reporting quality. Methods We performed a cross-sectional, meta-epidemiological study to determine adherence to CONSORT-PRO reporting guidelines in RCTs. We searched Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE for RCT publications investigating PNBs between 2006 and 2020. RCTs investigating PNBs that incorporated PROs as a primary or secondary outcome were included. All other studies, reviews, or publications without a PRO were excluded. Results In total, 65 RCTs met the inclusion criteria. Mean CONSORT-PRO adherence was 46.80 ± 17.36%, and trials that designated a PRO as the primary endpoint were more adherent than those in which the PRO was secondary (49.27 ± 16.58% versus 38.57 ± 17.92%; P = 0.035). Trials with ≥ 6-month follow-up were 16.24% more adherent than those with ≤ 3-month follow-up (P = 0.006). Studies that used a visual analog scale (VAS) or numeric rating scale (NRS) in combination with other PRO instruments were significantly more adherent than trials using VAS alone (P = 0.028). Conclusions Our meta-epidemiological review reveals substantial nonadherence to CONSORT-PRO guidelines in PNB trials. Although PROs are crucial for capturing patient-centered outcomes, they remain under-reported, especially when treated as secondary endpoints. Using diverse, validated measures beyond VAS/NRS and consistently applying CONSORT-PRO can enhance the quality, transparency, and clinical relevance of future trials. Targeted education for authors, editors, and clinicians—and expanded research on neuraxial techniques—will further strengthen reporting standards and the interpretability of anesthesia evidence.Keywords
This publication has 31 references indexed in Scilit:
- Reporting of Patient‐Reported Outcome Measures in Randomized Controlled Trials on Shoulder Rotator Cuff Injuries Is Suboptimal and Requires StandardizationArthroscopy, Sports Medicine, and Rehabilitation, 2022
- Quality of patient‐reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic reviewCancer Medicine, 2021
- Meta-epidemiological study of publication integrity, and quality of conduct and reporting of randomized trials included in a systematic review of low back painJournal of Clinical Epidemiology, 2021
- Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological studyJournal of Clinical Epidemiology, 2020
- A cross-sectional study of the reporting quality of pilot or feasibility trials in high-impact anesthesia journalsCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2018
- The use of systematic reviews to justify anaesthesiology trials: A meta‐epidemiological studyEuropean journal of pain, 2018
- Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extensionQuality of Life Research, 2017
- A Systematic Review of Patient‐reported Outcomes in Randomized Controlled Trials of Unplanned General SurgeryWorld Journal of Surgery, 2015
- Quality of patient‐reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient‐reported outcome extension: A pooled analysis of 557 trialsCancer, 2015
- Reporting of Patient-Reported Outcomes in Randomized TrialsJAMA, 2013